frontiers journal impact factor 2022ruth putnam the crucible

The main research efforts in this field are currently focused on Palbociclib and Abemaciclib. The impact factor is calculated by dividing the number of times the articles are cited in the last two years by the total number of publications in those two years. It is, Read More (Updated 2023) PNAS Impact Factor 2023Continue, In this post, apart from Nature Reviews Neurology Impact Factor, I have tried to compile all the necessary information a research scholar would seek before publishing an article in the journal. Dai K, Li C, Liang L, Rong MG, Orf J, Keegan K, et al. Frontiers in Cardiovascular Medicine Impact Factor 2022 Figure10 The most frequent mechanisms or treatment of resistance to CDK46 inhibitors in Web of Science Core Collection. The article investigates the mechanism by which acquired resistance to CDK4/6 inhibitors is generated by amplification of CCNE1 or deletion of Rb1 to bypass the cyclin D1-CDK4/6 complex and verifies that acquired resistance generated by CCNE1 amplification can be resolved by targeting CDK2 (63). [dissertation/masters thesis]. About Frontiers in Molecular Biosciences Journal Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, et al. In the process of exploring the mechanism and therapeutic content of CDK46 inhibitor resistance, we selected only Clinical Study, Clinical Trial, Controlled Clinical Trail, Randomized Controlled Trial, and Research Support from PubMed, and Article plus Meeting Abstract from Web of Science for statistical purposes. You can download the complete PDF list of UGC approved Journal for 2022. Verzeichnis der Kinderkrippen, Kindergrten und Kinderhorte, Tagesbetreuunmgseinrichtungen fr Kinder, in Baden-Wrttemberg. As of 2022, Frontiers publishes over 185 academic journals, including 48 journals indexed within the Science Citation Index Expanded, and 4 journals indexed within the Social Sciences Citation Index, [6] with a total of 51 journals ranked with an impact factor. J Clin Oncol (2017) 35(25):287584. Hallmarks of cancer: The next generation. Phase iii randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Monaleesa-3. Frontiers in Microbiology Cancer Res (2017) 77(9):248899. The ten institutions with the most publications in the field of CDK4/6 inhibitor resistance have been listed in Supplementary Figure S2. doi:10.1056/NEJMoa1607303, 12. Cowan, W. M., Jessell, T. M., and Zipursky, S. L. (1997). Figure11 The most frequent mechanisms or treatment of resistance to CDK46 inhibitors in PubMed. Deregulated immune pathway associated with palbociclib resistance in preclinical breast cancer models: Integrative genomics and transcriptomics. Hendricks, J., Applebaum, R., and Kunkel, S. (2010). doi:10.1158/2159-8290.Cd-18-0830, 38. The aim is to identify trends in the publication of common research topics, the focus of published journals, and the authorship of dominant countries. Impact Factor (IF) or often called journal impact factor (JIF) is an index provided by an analytics company namedClarivate. The citation indexes of Web of Science included SCI-EXPANDED, SSCI, AHCI, CPCI-S, CPCI-SSH, BKCI-SSH, ESCI, CCR-EXPANDED, and IC. Pi3k mutations detected in liquid biopsy are associated to reduced sensitivity to Cdk4/6 inhibitors in metastatic breast cancer patients. Monarch 3: Abemaciclib as initial therapy for advanced breast cancer. The 15 relevant mechanisms or treatments with the highest frequency of occurrence were selected. Smith, J. The third most-cited journal in its field, which promotes discussion around inter-sectoral public health challenges spanning health promotion to climate change, transportation, environmental change. Frontiers in Genetics IS is decreased by a factor of 0.9 and approximate percentage change is -20.32% when compared to preceding year 2021, which shows a falling trend. Due to the presence of three active metabolites of similar potency to abemaciclib, they have different IC50 values for CDK4 and CDK6. doi:10.1016/s0092-8674(00)81519-6, 7. Frontiers in Oncology Impact Factor 2018 - 4.137. Frontiers | CDK4/6 inhibitor resistance: A bibliometric analysis CDK4/6 inhibitors can inactivate cyclin D-CDK4/6 from G1 to S phase and block Rb phosphorylation (7). About Nature Climate Change Journal Nature Climate Change is a monthly peer-reviewed scientific journal published by Nature Publishing Group covering all aspects of research, Read More Nature Climate Change Impact Factor 2022Continue, Here in this post, you will find the most updated UGC approved Journal list in 2022. Words with occurrences greater than 5 were counted in the co-occurrence statistics. The SCImago Journal Rank (SJR) indicator is a measure of the scientific influence of scholarly journals that accounts for both the number of citations received by a journal and the importance or prestige of the journals where the citations come from. Frontiers in Oncology Impact Factor 2021 - 5.738 (updated 29 June 2022) Frontiers in Oncology Impact Factor 2022. Genes (2021) 12(2):14. doi:10.3390/genes12020159, 36. The Web of Science database article authors institution is not duplicated, while the PubMed database counts the frequency of occurrence of article authors institutions. Dean JL, Thangavel C, McClendon AK, Reed CA, Knudsen ES. See our editorial guidelines for everything you need to know about Frontiers peer review process. Frontiers in Molecular Biosciences Impact Factor 2022. Slc36a1-Mtorc1 signaling drives acquired resistance to Cdk4/6 inhibitors. Investigational New Drugs (2014) 32(5):82537. Start your submission and get more impact for your research by publishing with us. Frontiers in Animal Science. Genomics technologies include NGS, microarrays, informatics, quality control, automation, PCR and qPCR and CRISPR for inherited disease, cancer genomics, and infectious disease research. The main research in the field of CDK4/6 inhibitor resistance is concentrated in the United States. All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. doi:10.1002/jcph.1584, 30. Sledge GW Jr., Toi M, Neven P, Sohn J, Inoue K, Pivot X, et al. OncoTarg Ther (2021) 14:292939. Impact Factor of the Journal in 2022 = 500/100 = 5. Gerontologist 50, 284-293. 6 sections 340 articles 495,327 article views. Nat Commun (2021) 12(1):1. doi:10.1038/s41467-021-25901-z, 45. Other studies also revealed some of the causes of acquired resistance like activation of oncogenic growth factor signaling pathways, and changes in metabolic function (1820). doi:10.1016/s1470-2045(15)00613-0, 25. Phase I/Ii trial of exemestane, ribociclib, and everolimus in women with Hr+/Her2(-) advanced breast cancer after progression on Cdk4/6 inhibitors (Triniti-1). doi:10.1007/s10637-014-0120-7, 34. Cancer Res (2016) 76:1. doi:10.1158/1538-7445.Sabcs15-p3-06-02, 42. Malorni Luca appears alongside Prof. Migliaccio Ilenia in most of his published articles, covering basic research on gene expression that inactivates RB function, potential biomarkers of therapeutic resistance, and inhibition of CDK7, as well as occasional review articles on current resistance research or key breakthroughs (5862). Endocrinol. Impact Factor of the Journal in 2022 = 500/100 = 5 List of Journals with highest Impact Factor Click here to download the above list of journals with the highest impact factor Complete Journal Impact Factor List 2022 - PDF, EXCEL List of Scopus Index Journal How To Find Scopus Index Journal All authors contributed to the article and approved the submitted version. Frontiers in Psychology Impact Factor 2022. The top cited articles related to CDK4/6 inhibitors for the resistance mechanisms or therapeutics addressed in the chart have been listed. The acceptance rate of a journal is the ratio of the number of articles submitted to the number of articles published. Supplementary Table4 | 10 most productive countries in PubMed. Author guidelines Ready to publish? A world apart? Frontiers in Pharmacology Impact Factor 2022 D. H. Evans (Boca Raton, FL: CRC Press), 375-405. doi:10.1016/s0140-6736(20)32381-3, 11. (Table3, Figure6, Supplementary Table S4) The country relationship and country distribution were drawn based on the number of publications and co-authors. CiteScore (CS) of an academic journal is a measure reflecting the yearly average number of citations to recent articles published in that journal. Expanding the Journal Impact Factor to all Web of Science Core collection journals will provide more transparency around the impact these journals will bring to their research communities," a spokesperson for Frontiers said. The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor-positive metastatic breast cancer. In Web of Science, the average number of citations per article in China is 15.06 and the rate of international collaboration among authors is 13.8%, while the average citations and international collaboration of articles in Italy are not significantly different from those in the United State. Therapeutic Cdk4/6 inhibition in breast cancer: Key mechanisms of response and failure. The frequencies of PI3K alone, PI3K-AKT, and PI3K-AKT-mTOR were 59, 99, and 113, respectively. About Frontiers in Pharmacology Journal Frontiers in Pharmacology is pea er-reviewed, open access, journal published by Frontiers Media Group. 12:917707. doi: 10.3389/fonc.2022.917707. Loibl S, Poortmans P, Morrow M, Denkert C, Curigliano G. Breast cancer. Mdm2 antagonists overcome intrinsic resistance to Cdk4/6 inhibition by inducing P21. You can download the Harvard style here Frontiers in Psychology Endnote Style and Frontiers in Psychology Zotero Style, The ISO 4 standard abbreviation for abstracting, indexing, and referencing purposes of Frontiers in Psychology is FRONT. Bridging the gap between theory and applied social gerontology. Cyclin D-CDK4/6 complex binding to p21 or p27 generates a holoenzyme that phosphorylates retinoblastoma proteins (Rb) (35), while inducing partial derepression of E2F and expression of cell cycle protein E (cyclin E) (6). About Frontiers in Pharmacology Journal Energetic Materials Frontiers - Impact Factor, Overall Ranking, Rating Agilent Clinical Research | Agilent Frontiers in Immunology Impact Factor 2022-2023 Table4 The most globally cited articles on resistance to CDK4/6 inhibitors. Oncotarget (2017) 8(41):69493507. A gene expression signature of retinoblastoma loss-of-Function predicts resistance to neoadjuvant chemotherapy in er-Positive/Her2-Positive breast cancer patients. Our efficient and rigorous peer review means youll get a decision on your manuscript in just 77 days. 2022 Volume 3 - 2021 . In malignant tumors, CDKs are usually more active, thus generating a sustained proliferative signal (1, 2). J Doc (1948) 4(3):198203. (Figure8) The same color represents the same clustering and the size of the circle represents the frequency of occurrence. Method and apparatus for eye tracking and monitoring pupil dilation to evaluate cognitive activity. All these drugs are approved for use in combination with nonsteroidal aromatase inhibitors in patients with metastatic hormone receptor +/HER2- breast cancer. (2008) Post-structuralist discourse relative to phenomological pursuits in the deconstructivist arena. The rest of the mentioned therapies include MEK inhibition, FGFR inhibition, MDM2 inhibition, CDK7 inhibition, immunotherapy, etc (41, 5156). The terms with high co-occurrence frequency are concentrated in both clinical application and drug experiments, such as combination, double-blind, therapy, phase-1, human, cell line, and so on. Migliaccio Ilenia, also from Prato Hospital, contributed to this article as well. Frontiers in Psychology Impact Factor 2022 Geoscience Frontiers | Journal | ScienceDirect.com by Elsevier (Accession No. Pharmacol Res (2020) 156:104686. doi:10.1016/j.phrs.2020.104686, 3. Mol Syst Biol (2017) 13(10):15. doi:10.15252/msb.20167321, 44. Gerontologist 50, 284-293. Cancer Res (2020) 80(16):2. doi:10.1158/1538-7445.Am2020-1903, 39. The combination of CDK4/6 inhibitors did improve the prognosis of patients compared to endocrine therapy alone, but the inevitable problem was that 25%35% of patients did not respond, and almost all patients eventually acquired resistance (17). Breast Care (2017) 12(5):3048. Specific inhibition of cyclin-dependent kinase 4/6 by pd 0332991 and associated antitumor activity in human tumor xenografts. Advances in therapy for hormone receptor (Hr)-positive, human epidermal growth factor receptor 2 (Her2)-negative advanced breast cancer patients who have experienced progression after treatment with Cdk4/6 inhibitors. Perdiguero P, Venturas M, Cervera MT, Gil L, Collada C. Data from: Massive sequencing of Ulms minors transcriptome provides new molecular tools for a genus under the constant threat of Dutch elm disease.

Get Your Guide Rovaniemi, Day Trips From Crestview, Fl, Articles F